603880.Ss
603880.SS operates in the healthcare services and equipment industry, primarily generating revenue through the production and distribution of medical equipment and supplies.
Business. 603880.SS operates in the healthcare services and equipment industry, primarily generating revenue through the production and distribution of medical equipment and supplies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
603880.SS operates in the healthcare services and equipment industry, primarily generating revenue through the production and distribution of medical equipment and supplies.
The company's capital structure is heavily leveraged, with a debt-to-equity ratio of 2.62, indicating a significant reliance on debt financing. Despite a current ratio of 0.49, which suggests limited short-term liquidity, the company reported an operating cash flow of 47.73 million CNY, though this was offset by a negative free cash flow of -94.96 million CNY. The negative net cash position after subtracting total debt raises concerns about the company's ability to meet long-term obligations.
Profitability metrics are severely negative, with a return on equity of -57.4% and a return on assets of -10.96%, both well below industry norms. The company reported a net loss of 101.71 million CNY and an operating loss of 92.34 million CNY, indicating a significant decline in operational performance. These figures suggest the company is struggling to generate returns that meet the cost of capital or industry benchmarks.
The company's revenue is not segmented by geographic region or product line in the available data, making it difficult to assess geographic or product concentration risks. However, the lack of diversification in the disclosed financials implies potential vulnerability to regional or market-specific disruptions.
The company's growth trajectory is negative, with a net loss and declining operating income reported in the latest financial period. There is no indication of a turnaround in the near term, and the company's capital expenditures of -13.20 million CNY suggest a reduction in investment in long-term growth. The absence of positive revenue growth or margin expansion further supports a cautious outlook.
Risk factors include a high debt load and negative free cash flow, which could limit the company's flexibility in responding to market changes. The risk assessment indicates a medium liquidity risk and a low dilution risk, though the negative net cash position after debt raises concerns about the company's ability to service its obligations. No significant dilution events are currently expected, but the company's financial position may necessitate additional financing in the future.
Recent events, including the latest financial filing, highlight the company's deteriorating financial performance and liquidity constraints. No recent transcripts or filings provide additional context on strategic initiatives or operational improvements.
- The company is experiencing significant financial distress, with a net loss and negative returns on equity and assets.
- The capital structure is highly leveraged, with a debt-to-equity ratio of 2.62, raising concerns about long-term solvency.
- The company's liquidity position is weak, with a current ratio of 0.49 and negative free cash flow.
- There is no indication of a near-term turnaround in profitability or cash flow generation.
- The company's financial position may necessitate additional financing, which could increase leverage or lead to dilution.
- **margin_outlook_rationale**: Margins are expected to remain negative due to declining operating income and net losses.
- **rd_outlook_rationale**: No specific R&D outlook is available, but the company's financial constraints may limit investment in innovation.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 603880.SS Market data — financials · 2026-05-27